QR Kodea

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

Abstract Introduction There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention. Reported are the results from the first head-to-head study of two CGRP antagonists, galcanezumab (monoclonal antibody) versus...

Deskribapen osoa

Gorde:
Egile Nagusiak: Todd J. Schwedt, Tina M. Myers Oakes, James M. Martinez, Bert B. Vargas, Hitendra Pandey, Eric M. Pearlman, Diane R. Richardson, Oralee J. Varnado, Michael Cobas Meyer, Peter J. Goadsby
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Adis, Springer Healthcare 2023-11-01
Saila:Neurology and Therapy
Gaiak:
Calcitonin gene-related peptide (CGRP)
CGRP antagonist
Galcanezumab
Gepant
Head-to-head
Migraine
Sarrera elektronikoa:https://doi.org/10.1007/s40120-023-00562-w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak